louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05569135: Debridement and Laser Ablation Versus Debridement Alone in Pilonidal Disease
Official title: Debridement and Laser Ablation Versus Debridement Alone in Pilonidal Disease: Retrospective Analysis of Mid-term Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pilonidal Disease
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2022-10-06
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female and males older than 18 years old

Brief summary: This study aims to investigate the effect of laser ablation (LA) in minimally invasive management of pilonidal disease (PD).

Data of the patients with PD who were eligible for simple debridement have been prospectively collected since March 2018, when laser ablation treatment came into use in our institution. Laser ablation treatment was offered to all eligible patients. All the patients underwent debridement (removal of hair and/or necrotic tissues through pits using a clamp/curette/brush) of PD; LA was added to the procedure in patients who were willing to have LA. The surgical outcome of two procedures was compared. The primary outcome measure was recurrence at 36 months.


Eligibility criteria: Inclusion Criteria:

* Patients with Class III, IV, and V pilonidal disease according to Tezel Navicular Area Classification
* Patients who underwent debridement for pilonidal disease

Exclusion Criteria:

* Patients with acute abscess (Tezel Class II)
* Antibiotic use within 4 weeks before surgery
* Patients lost to follow-up at 3,7 and 30 days; 6, 12 and 36 months

Primary outcomes:
measure: disease recurrence at 36 months
timeFrame: 36 months
Secondary outcomes:
measure: Complications after the procedure
timeFrame: 1 month
measure: Incidence of adverse events
timeFrame: 1 month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Medipol Bahcelievler Hospital
state: Other (Non U.s.)
Study officials:
affiliation: Medipol University
name: Naciye Cigdem Arslan, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tezel E. A new classification according to navicular area concept for sacrococcygeal pilonidal disease. Colorectal Dis. 2007 Jul;9(6):575-6. doi: 10.1111/j.1463-1318.2007.01236.x. No abstract available.
Clinical trial NCT01424735: TLR-9 Antagonism in Steroid Resistant Optic Neuritis
Official title: Outcomes of TLR-9 Antagonism in Steroid Resistant Optic Neuritis; A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Optic Neuritis
Keywords: Best corrected Visual Acuity
Pupillary Reaction
Colour vision
Disc edema
Lead sponsor: Sudhalkar Eye Hospital
Sponsor class: OTHER
First posted: 2011-08-29
Enrollment: 8
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Although idiopathic steroid resistant optic neuritis is very uncommon, there is no established treatment protocol for such patients. Toll like receptors (TLRs) especially TLR-9 has been shown to play a role in the pathogenesis of optic neuritis. This small case series aims to determine whether immunomodulators directed specifically at TLR-9(i.e. TLR-9 antagonism)play any role in improving the visual function in such patients.


Eligibility criteria: Inclusion Criteria:

Unilateral Steroid Resistant Optic Neuritis

Exclusion Criteria:

* bilateral optic neuritis
* Associated Systemic disease
* Prior treatment received

Primary outcomes:
measure: Improvement in all aspects of visual function
timeFrame: upto 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baroda
country: India
facility: Sudhalkar Eye Hospital
state: Gujarat
Study officials:
affiliation: Thakore Eye Hospital, Ahmedabad
name: Bakulesh M Khamar, M.S. Ophthalmology
role: PRINCIPAL_INVESTIGATOR
affiliation: M & J Institute Of Ophthalmology
name: Mayuri B Khamar, M.S.Ophthalmology
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04473235: Better Memory With Literacy Acquisition Later in Life
Official title: Better Memory With Literacy Acquisition Later in Life
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Memory Impairment
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Federal University of Minas Gerais
name: National Institute on Aging (NIA)
First posted: 2020-07-16
Enrollment: 108
Sex: ALL
Minimum age (years): 40
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to discover whether acquiring basic-literacy in adulthood can improve episodic memory and brain structural and functional connectivity. In a collaborative project between Brazil and USA, the investigators will use a randomized controlled trial approach to leverage the level of evidence of the benefits of basic adult-education as a possible cognitive reserve builder. If successful, the study's findings will be important in shaping policies targeting increasing access to late-life education to reduce dementia risk.


Eligibility criteria: Inclusion Criteria:

Being illiterate (TOFHLA score \<53) and availability to participate in the study for at least 12 months

Exclusion Criteria:

A) Presence of remarkable cognitive complains and/or decompensated psychiatric illness (depression and anxiety) and/or current substance abuse such as alcohol and illicit drugs use.

B) Objective cognitive impairment: score of 2 standard deviations or bellow for age and education on the Mini-Mental State Evaluation (MMSE) and/or score of 6 or lower on the delayed recall task from the Brief Cognitive Battery.

C) History of previously diagnosed dyslexia D) Formal MRI contraindications including metal or claustrophobia. E) Severe structural lesions detected by MRI.

Primary outcomes:
measure: Episodic Memory Improvement
timeFrame: Baseline and 6 months
Secondary outcomes:
measure: Change in Brain Connectivity
timeFrame: Baseline and 6 months
Other outcomes:
Locations:
city: Belo Horizonte
country: Brazil
facility: Universidade Federal de Minas Gerais
state: Minas Gerais
Study officials:
affiliation: UFMG
name: Elisa Resende, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Lea T Grinberg, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05712135: Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases
Official title: Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: The Effect of Cuff Pressure on Postoperative Dysphagia
Keywords: cuff pressure
postoperative dysphagia
different positions in neurosurgery
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2023-02-03
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neurosurgery patients between the ages of 18-70 under general anesthesia in the operating room between February 2022 and April 2022.

Brief summary: We aimed to measure the change in cuff pressure in different positions in neurosurgery cases and to investigate the effect of case length on cuff pressure.

Detailed description: It is an observational study, the cuffs of the endotracheal tubes of the patients who were intubated under general anesthesia between February 2023 and May 2023 will be inflated at 25 cm H2O pressure, and then the pressure line and the pilot balloon will be connected to the anesthesia monitor. The cuff pressure of the patient will be measured from the pilot balloon throughout the case and recorded at half-hour intervals. Postoperative sore throat will be evaluated on the VAS scale. Postoperative cough, hoarseness, and dysphagia symptoms will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Neurosurgery patients between the ages of 18-70 ages
* American Society of Anesthesiologist score I-II-III-IV

Exclusion Criteria:

* Patients with previous tracheostomy
* Patients with tracheal stenosis
* Patients considered as difficult intubation
* Patients who have had more than one intubation attempt
* Patients with an ASA score greater than 4
* Patient who has difficulty understanding visual analog scale (VAS) scores
* Language / communication barrier
* Patients younger than 18 years old

Primary outcomes:
measure: The effect of cuff pressure on postoperative sore throat
timeFrame: 24 hours
Secondary outcomes:
measure: Comparison of cuff pressure changes with cuff time according to groups
timeFrame: 8 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06878235: Validation of the French Version of the Primary Lateral Sclerosis Functioning Rating Scale (PLSFRS)
Official title: Validation of the French Version of the PLSFRS Scale
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lateral Sclerosis
Keywords: Scale
Lead sponsor: University Hospital, Tours
Sponsor class: OTHER
First posted: 2025-03-14
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with primary lateral sclerosis

Brief summary: This is a national, multicentric, prospective, descriptive study evaluating the psychometric properties of the French version PLSFRS scale

Detailed description: This is a prospective study conducted in 8 French ALS centers which will enroll 80 patients with PLS. All these patients will undergo an evaluation of their functional status from the ALSFRS-r and PLSFRS scales. All patients will be evaluated at 3 time points (T0,M6 at the outpatient clinic) and at M3 remotely. The aim of the study will be to validate a trans-cultural and psychometric version of the PLSFRS available for the French PLS population.

Eligibility criteria: Inclusion Criteria:

* Patients with primary lateral sclerosis (PLS)
* Age over 18 years
* Informed consent signed
* Patients cared in a French ALS centre

Exclusion Criteria:

* patients with no oral and written command of the French language
* Patients unable to answer a questionnaire
* Opposition to data processing

Primary outcomes:
measure: French version of the PLSFRS scale
timeFrame: inclusion and 6 months
Secondary outcomes:
measure: Change Global Impression (CGI) scale
timeFrame: 6 months
Other outcomes:
Locations:
city: Brest
country: France
facility: University hospital
city: Clermont-Ferrand
country: France
facility: University hospital
city: Lille
country: France
facility: University hospital
city: Limoges
country: France
facility: University hospital
city: Lyon
country: France
facility: University hospital
city: Nice
country: France
facility: University Hospital
city: Tours
country: France
facility: University hospital
Study officials:
affiliation: University Hospital, Tours
name: Philippe CORCIA, PR
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00114335: Epidemiologic Data of Patients in a Teaching Hospital
Official title: Prevalence of Impaired Renal Function in Medical Inpatients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Diseases
Obesity
Keywords: low molecular weight heparin
unfractionated heparin
Lead sponsor: Luzerner Kantonsspital
Sponsor class: OTHER
First posted: 2005-06-15
Enrollment: 352
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All patients hospitalized at the defined days (two days) at Kantonsspital Luzern, Department of Medicine

Brief summary: This small cross-sectional epidemiological study is designed to evaluate the prevalence of the following parameters in hospitalized patients in a tertiary teaching hospital (medical department only):

* kidney insufficiency
* obesity
* use of unfractionated heparins / low molecular weight heparins
* other drugs effecting the hemostatic system

Detailed description: This small cross-sectional epidemiological study is designed to evaluate the prevalence of the following parameters in hospitalized patients in a tertiary teaching hospital (medical department only):

* kidney insufficiency
* obesity
* use of unfractionated heparins / low molecular weight heparins
* other drugs effecting the hemostatic system

Eligibility criteria: Inclusion Criteria:

* All patients hospitalized at the defined days (two days) at Kantonsspital Luzern, Department of Medicine

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Luzern
country: Switzerland
facility: Kantonsspital Luzern
state: LU
Study officials:
affiliation: Kantonsspital Luzern, Hematology
name: P Schmid, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kantonsspital Luzern, Nephrology
name: A G Fischer, MD
role: STUDY_DIRECTOR
affiliation: Kantonsspital Luzern, Hematology
name: W A Wuillemin, MD, PhD
role: STUDY_CHAIR
References:
citation: Schmid P, Fischer AG, Wuillemin WA. Prevalence of impaired renal function in medical inpatients. Swiss Med Wkly. 2007 Sep 8;137(35-36):514. doi: 10.4414/smw.2007.11903. No abstract available.
Clinical trial NCT03853135: Assessment of Endocan Serum Levels in Patients With Behcet Disease
Official title: Assessment of Endocan Serum Levels in Patients With Behcet Disease: Relation to Clinical Parameters and Disease Status
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behçet
Keywords: Behçet disease
endocan
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2019-02-25
Enrollment: 84
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study will be carried out on two groups:

• Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD .

Group (II): including 42 age and sex matching healthy volunteers as control group.

Brief summary: The aim of our study was to assess serum endocan levels in patients with Behcet disease and to correlate it with various disease clinical and laboratory parameters of disease activity as well as carotid intima media thickness.

Detailed description: This study will be carried out on two groups:

• Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD .

Group (II): including 42 age and sex matching healthy volunteers as control group.

(A) Clinical evaluation

1. Complete history taking.
2. Thorough clinical examination including opthalmologic evaluation .
3. Disease activity using The Behcet's disease current activity form (BD-DAF) . (B) Laboratory assessment:

All patients will be subjected to the following measurements:

1. ESR
2. CRP
3. CBC
4. liver and kidney function tests

d) Serum Endocan level e)triglycrides f) cholestrol C) carotid intima media thickness

Eligibility criteria: Inclusion Criteria:

* patients with Behcets disease fulfilling the International Criteria for BD .

Exclusion Criteria:

* infection
* malignancy
* other connective tissue disease
* chronic liver disease
* chronic kidney disease
* Diabetes mellitus
* hypertension
* hyperlipidemia

Primary outcomes:
measure: the Behcet's disease current activity form (BDCAF)
timeFrame: : through study completion, an average of 6 months
measure: Erythrocyte sedimentation rate (ESR)
timeFrame: : through study completion, an average of 6 months
measure: C reactive protein (CRP)
timeFrame: : through study completion, an average of 6 months
measure: carotid intima media thickness
timeFrame: : through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Benha University Hospital
state: Qalubiya
Study officials:
affiliation: Benha university- Qaluibya- Egypt
name: Waleed Hassan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04046835: The Effect of Patient Position on the External Haller Index Value Among Patients With Pectus Excavatum
Official title: The Effect of Patient Position on the External Haller Index Value Among Patients With Pectus Excavatum
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pectus Excavatum
Keywords: Three-dimensional optical surface scanning
Patient position
Lead sponsor: Zuyderland Medisch Centrum
Sponsor class: OTHER
First posted: 2019-08-06
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that received a three-dimensional optical surface scan to quatify their pectus deformity utilizing the external Haller Index. Patients were retrospectively recruited from the 3DPECTUS study (METCZ20190048; NCT03926078).

Brief summary: Pectus excavatum is the most common anterior chest wall deformity, affecting up to 1:400 of newborns. The current gold standard to quantify the extent of deformity is by calculating the Haller Index based on a Computed Tomography (CT)-scan. However, as such scans inescapably imply exposure to ionizing radiation, novel imaging techniques have been investigated. Three-dimensional optical surface scanning is a promising new technique to acquire the trunks' three-dimensional (3D) surface topography. Based on this 3D scan, one is able to calculate the external Haller Index that is known to highly correlate with the conventional gold standard Haller Index that is based on internal measures. Both the conventional and external Haller Index are known to be affected by the respiratory phase in which the scan is acquired, however, what is the effect of patient position on the external Haller Index, and if affected, how should one correct for this phenomenon? To investigate this, a retrospective single-centre pilot study will be conducted.


Eligibility criteria: Inclusion Criteria:

* Patients that received a three-dimensional optical surface scan to quantify their pectus deformity

Exclusion Criteria:

* None

Primary outcomes:
measure: Patient position
timeFrame: 5 months
Secondary outcomes:
measure: Manual versus automatic alignment of patient position
timeFrame: 5 months
Other outcomes:
Locations:
city: Heerlen
country: Netherlands
facility: Zuyderland Medical Centre
state: Limburg
Study officials:
References:
Clinical trial NCT00002335: The Safety and Effectiveness of 524W91
Official title: A Phase I, Randomized, Single-Dose, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of 524W91
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Antiviral Agents
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.

Detailed description: Patients are randomized to receive six single escalating doses of 524W91 or placebo, with each dose separated by at least a 6-day washout interval. In the time between 2 of the doses, the effect of food on pharmacokinetics will be investigated, with one dose administered in conjunction with a high-fat meal and one dose administered in a fasted state.

Eligibility criteria: Inclusion Criteria

Patients must have:

* Documented HIV infection.
* CD4 count \>= 200 cells/mm3.
* No active opportunistic infection.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Malignancy or other condition that would confound study assessment or interfere with ability to complete the study.
* Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with gastrointestinal absorption.

Concurrent Medication:

Excluded on the day of each dose:

* Antiretrovirals.
* Any prescription or over-the-counter medication.
* Alcoholic beverages.
* Coffee, tea, and other xanthine-containing beverages and foods.

Patients with the following prior conditions are excluded:

History of hepatitis, pancreatitis, or cardiomyopathy within the past 5 years.

Prior Medication:

Excluded:

* Antiretrovirals within 24 hours prior to each dose.
* Any prescription or over-the-counter medications within 48 hours prior to each dose.
* Alcoholic beverages within 48 hours prior to each dose. Current alcohol or illicit drug use that may affect patient compliance.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: ViRx Inc
state: California
Study officials:
References:
Clinical trial NCT01621035: Objective Assessment of Physical Activity in Older Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Functionality
Strength
Validity During Daily Activities
Physical Activity
Older Adults
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2012-06-15
Enrollment: 90
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Older adults (\> 70 years)

Brief summary: The purpose of the present study is to evaluate the validity of 2 objective measures of physical activity among older adults. In addition, the investigators will examine the influence of functionality, walking aids, walking speed and step length on the accuracy.


Eligibility criteria: Inclusion Criteria:

* \> 70 years

Exclusion Criteria:

* recent cardiovascular event
* vestibular disorder or fracture (4 months)
* severe dementia
* oxygen supplementation during daily activities
* not able to perform daily activities

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Faculty of Kinesiology and Rehabilitation Sciences
Study officials:
References: